At the news
? NEUTRALIMPACT 4/10 8-K filed May 5, 2026 at 08:08 ET
Cogent Biosciences reported Q1 2026 net loss of $97.4M, wider than the $72.0M loss in Q1 2025, driven by increased R&D and G&A spending ahead of planned bezuclastinib launches. The company ended the quarter with $866.4M in cash, with two NDAs under FDA review and a PDUFA date of December 30, 2026 for NonAdvSM. The wider loss and lack of revenue are consistent with a pre-commercial biotech, but the stock will trade on regulatory catalysts, not quarterly financials.
- Net loss of $97.4M in Q1 2026 vs $72.0M in Q1 2025
- Cash, cash equivalents and marketable securities of $866.4M as of March 31, 2026
- FDA accepted NDA for bezuclastinib in NonAdvSM with PDUFA date of December 30, 2026
- NDA for bezuclastinib in GIST submitted under RTOR program; APEX NDA for AdvSM expected in 1H 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access